Cancer Research Cancer Research Funding Available Jordan
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dasgupta, B.
Right arrow Articles by Gutmann, D. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dasgupta, B.
Right arrow Articles by Gutmann, D. H.
[Cancer Research 65, 2755-2760, April 1, 2005]
© 2005 American Association for Cancer Research

Cell and Tumor Biology

Proteomic Analysis Reveals Hyperactivation of the Mammalian Target of Rapamycin Pathway in Neurofibromatosis 1–Associated Human and Mouse Brain Tumors

Biplab Dasgupta1, Yijun Yi1, David Y. Chen2, Jason D. Weber2 and David H. Gutmann1

Departments of 1 Neurology and 2 Internal Medicine, Washington University School of Medicine, St. Louis, Missouri

Requests for reprints: David H. Gutmann, Department of Neurology, Box 8111, 660 South Euclid Avenue, St. Louis, MO 63110. Phone: 314-362-7379; Fax: 314-362-2388; E-mail: pouchera{at}neuro.wustl.edu.

Individuals with the tumor predisposition syndrome, neurofibromatosis 1 (NF1), are prone to development of nervous system tumors, including neurofibromas and pilocytic astrocytomas. Based on the ability of the NF1 gene product (neurofibromin) to function as a GTPase activating protein for RAS, initial biologically based therapies for NF1-associated tumors focused on the use of RAS inhibitors, but with limited clinical success. In an effort to identify additional targets for therapeutic drug design in NF1, we used an unbiased proteomic approach to uncover unanticipated intracellular signaling pathways dysregulated in Nf1-deficient astrocytes. We found that the expression of proteins involved in promoting ribosome biogenesis was increased in the absence of neurofibromin. In addition, Nf1-deficient astrocytes exhibit high levels of mammalian target of rapamycin (mTOR) pathway activation, which was inhibited by blocking K-RAS or phosphatidylinositol 3-kinase activation. This mTOR pathway hyperactivation was reflected by high levels of ribosomal S6 activation in both Nf1 mutant mouse optic nerve gliomas and in human NF1-associated pilocytic astrocytoma tumors. Moreover, inhibition of mTOR signaling in Nf1–/– astrocytes abrogated their growth advantage in culture, restoring normal proliferative rates. These results suggest that mTOR pathway inhibition may represent a logical and tractable biologically based therapy for brain tumors in NF1.

Key Words: neurofibromatosis 1 • RAS • mTOR • astrocytoma • glioma




This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
C. Gregorian, J. Nakashima, S. M. Dry, P. L. Nghiemphu, K. B. Smith, Y. Ao, J. Dang, G. Lawson, I. K. Mellinghoff, P. S. Mischel, et al.
PTEN dosage is essential for neurofibroma development and malignant transformation
PNAS, November 17, 2009; 106(46): 19479 - 19484.
[Abstract] [Full Text] [PDF]

Home page
 J Child NeurolHome page
A. J. Sievert and M. J. Fisher
Pediatric Low-Grade Gliomas
J Child Neurol, November 1, 2009; 24(11): 1397 - 1408.
[Abstract] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
C. Y. Zou, K. D. Smith, Q.-S. Zhu, J. Liu, I. E. McCutcheon, J. M. Slopis, F. Meric-Bernstam, Z. Peng, W. G. Bornmann, G. B. Mills, et al.
Dual targeting of AKT and mammalian target of rapamycin: A potential therapeutic approach for malignant peripheral nerve sheath tumor
Mol. Cancer Ther., May 1, 2009; 8(5): 1157 - 1168.
[Abstract] [Full Text] [PDF]

Home page
 J Child NeurolHome page
D. H. Gutmann
Using Neurofibromatosis-1 to Better Understand and Treat Pediatric Low-Grade Glioma
J Child Neurol, October 1, 2008; 23(10): 1186 - 1194.
[Abstract] [PDF]

Home page
 Cancer Res.Home page
B. Hegedus, D. Banerjee, T.-H. Yeh, S. Rothermich, A. Perry, J. B. Rubin, J. R. Garbow, and D. H. Gutmann
Preclinical Cancer Therapy in a Mouse Model of Neurofibromatosis-1 Optic Glioma
Cancer Res., March 1, 2008; 68(5): 1520 - 1528.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
J. Xu, F. A. Ismat, T. Wang, J. Yang, and J. A. Epstein
NF1 Regulates a Ras-Dependent Vascular Smooth Muscle Proliferative Injury Response
Circulation, November 6, 2007; 116(19): 2148 - 2156.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Neuroradiol.Home page
F.J. Wippold II, M. Lubner, R.J. Perrin, M. Lammle, and A. Perry
Neuropathology for the Neuroradiologist: Antoni A and Antoni B Tissue Patterns
AJNR Am. J. Neuroradiol., October 1, 2007; 28(9): 1633 - 1638.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. K. Sandsmark, H. Zhang, B. Hegedus, C. L. Pelletier, J. D. Weber, and D. H. Gutmann
Nucleophosmin Mediates Mammalian Target of Rapamycin-Dependent Actin Cytoskeleton Dynamics and Proliferation in Neurofibromin-Deficient Astrocytes
Cancer Res., May 15, 2007; 67(10): 4790 - 4799.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
G. C. Daginakatte and D. H. Gutmann
Neurofibromatosis-1 (Nf1) heterozygous brain microglia elaborate paracrine factors that promote Nf1-deficient astrocyte and glioma growth
Hum. Mol. Genet., May 1, 2007; 16(9): 1098 - 1112.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. K. Sharma, D. B. Mansur, G. Reifenberger, A. Perry, J. R. Leonard, K. D. Aldape, M. G. Albin, R. J. Emnett, S. Loeser, M. A. Watson, et al.
Distinct Genetic Signatures among Pilocytic Astrocytomas Relate to Their Brain Region Origin
Cancer Res., February 1, 2007; 67(3): 890 - 900.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. Yang, E. Jackson, B. M. Woerner, A. Perry, D. Piwnica-Worms, and J. B. Rubin
Blocking CXCR4-Mediated Cyclic AMP Suppression Inhibits Brain Tumor Growth In vivo
Cancer Res., January 15, 2007; 67(2): 651 - 658.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
W. Lavery, V. Hall, J. C. Yager, A. Rottgers, M. C. Wells, and M. Stern
Phosphatidylinositol 3-Kinase and Akt Nonautonomously Promote Perineurial Glial Growth in Drosophila Peripheral Nerves
J. Neurosci., January 10, 2007; 27(2): 279 - 288.
[Abstract] [Full Text] [PDF]

Home page
 Genes Dev.Home page
J. A. Walker, A. V. Tchoudakova, P. T. McKenney, S. Brill, D. Wu, G. S. Cowley, I. K. Hariharan, and A. Bernards
Reduced growth of Drosophila neurofibromatosis 1 mutants reflects a non-cell-autonomous requirement for GTPase-Activating Protein activity in larval neurons
Genes & Dev., December 1, 2006; 20(23): 3311 - 3323.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Charest, E. W. Wilker, M. E. McLaughlin, K. Lane, R. Gowda, S. Coven, K. McMahon, S. Kovach, Y. Feng, M. B. Yaffe, et al.
ROS Fusion Tyrosine Kinase Activates a SH2 Domain-Containing Phosphatase-2/Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Signaling Axis to Form Glioblastoma in Mice.
Cancer Res., August 1, 2006; 66(15): 7473 - 7481.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
F. Li, A. M. Munchhof, H. A. White, L. E. Mead, T. R. Krier, A. Fenoglio, S. Chen, X. Wu, S. Cai, F.-C. Yang, et al.
Neurofibromin is a novel regulator of RAS-induced signals in primary vascular smooth muscle cells
Hum. Mol. Genet., June 1, 2006; 15(11): 1921 - 1930.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
A. M. Munchhof, F. Li, H. A. White, L. E. Mead, T. R. Krier, A. Fenoglio, X. Li, J. Yuan, F.-C. Yang, and D. A. Ingram
Neurofibroma-associated growth factors activate a distinct signaling network to alter the function of neurofibromin-deficient endothelial cells
Hum. Mol. Genet., June 1, 2006; 15(11): 1858 - 1869.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. Dasgupta, Y. Yi, B. Hegedus, J. D. Weber, and D. H. Gutmann
Cerebrospinal Fluid Proteomic Analysis Reveals Dysregulation of Methionine Aminopeptidase-2 Expression in Human and Mouse Neurofibromatosis 1-Associated Glioma
Cancer Res., November 1, 2005; 65(21): 9843 - 9850.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.